Cargando…
Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls
Background: Heart failure with preserved ejection fraction (HFpEF) remains an ongoing therapeutic and diagnostic challenge to date. In this study we aimed for an analysis of the diagnostic potential of four novel cardiovascular biomarkers, GDF-15, H-FABP, sST2, and suPAR in HFpEF patients compared t...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230638/ https://www.ncbi.nlm.nih.gov/pubmed/32326570 http://dx.doi.org/10.3390/jcm9041130 |
_version_ | 1783535001453723648 |
---|---|
author | Jirak, Peter Pistulli, Rudin Lichtenauer, Michael Wernly, Bernhard Paar, Vera Motloch, Lukas J. Rezar, Richard Jung, Christian Hoppe, Uta C. Schulze, P. Christian Kretzschmar, Daniel Braun-Dullaeus, Rüdiger C. Bekfani, Tarek |
author_facet | Jirak, Peter Pistulli, Rudin Lichtenauer, Michael Wernly, Bernhard Paar, Vera Motloch, Lukas J. Rezar, Richard Jung, Christian Hoppe, Uta C. Schulze, P. Christian Kretzschmar, Daniel Braun-Dullaeus, Rüdiger C. Bekfani, Tarek |
author_sort | Jirak, Peter |
collection | PubMed |
description | Background: Heart failure with preserved ejection fraction (HFpEF) remains an ongoing therapeutic and diagnostic challenge to date. In this study we aimed for an analysis of the diagnostic potential of four novel cardiovascular biomarkers, GDF-15, H-FABP, sST2, and suPAR in HFpEF patients compared to controls as well as ICM, and DCM. Methods: In total, we included 252 stable outpatients and controls (77 DCM, 62 ICM, 18 HFpEF, and 95 controls) in the present study. All patients were in a non-decompensated state and on a stable treatment regimen. Serum samples were obtained and analyzed for GDF-15 (inflammation, remodeling), H-FABP (ischemia and subclinical ischemia), sST2 (inflammation, remodeling) and suPAR (inflammation, remodeling) by means of ELISA. Results: A significant elevation of GDF-15 was found for all heart failure entities compared to controls (p < 0.005). Similarly, H-FABP evidenced a significant elevation in all heart failure entities compared to the control group (p < 0.0001). Levels of sST2 were significantly elevated in ICM and DCM patients compared to the control group and HFpEF patients (p < 0.0001). Regarding suPAR, a significant elevation in ICM and DCM patients compared to the control group (p < 0.0001) and HFpEF patients (p < 0.01) was observed. An AUC analysis identified H-FABP (0.792, 95% CI 0.713–0.870) and GDF-15 (0.787, 95% CI 0.696–0.878) as paramount diagnostic biomarkers for HFpEF patients. Conclusion: Based on their differences in secretion patterns, novel cardiovascular biomarkers might represent a promising diagnostic tool for HFpEF in the future. |
format | Online Article Text |
id | pubmed-7230638 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72306382020-05-22 Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls Jirak, Peter Pistulli, Rudin Lichtenauer, Michael Wernly, Bernhard Paar, Vera Motloch, Lukas J. Rezar, Richard Jung, Christian Hoppe, Uta C. Schulze, P. Christian Kretzschmar, Daniel Braun-Dullaeus, Rüdiger C. Bekfani, Tarek J Clin Med Article Background: Heart failure with preserved ejection fraction (HFpEF) remains an ongoing therapeutic and diagnostic challenge to date. In this study we aimed for an analysis of the diagnostic potential of four novel cardiovascular biomarkers, GDF-15, H-FABP, sST2, and suPAR in HFpEF patients compared to controls as well as ICM, and DCM. Methods: In total, we included 252 stable outpatients and controls (77 DCM, 62 ICM, 18 HFpEF, and 95 controls) in the present study. All patients were in a non-decompensated state and on a stable treatment regimen. Serum samples were obtained and analyzed for GDF-15 (inflammation, remodeling), H-FABP (ischemia and subclinical ischemia), sST2 (inflammation, remodeling) and suPAR (inflammation, remodeling) by means of ELISA. Results: A significant elevation of GDF-15 was found for all heart failure entities compared to controls (p < 0.005). Similarly, H-FABP evidenced a significant elevation in all heart failure entities compared to the control group (p < 0.0001). Levels of sST2 were significantly elevated in ICM and DCM patients compared to the control group and HFpEF patients (p < 0.0001). Regarding suPAR, a significant elevation in ICM and DCM patients compared to the control group (p < 0.0001) and HFpEF patients (p < 0.01) was observed. An AUC analysis identified H-FABP (0.792, 95% CI 0.713–0.870) and GDF-15 (0.787, 95% CI 0.696–0.878) as paramount diagnostic biomarkers for HFpEF patients. Conclusion: Based on their differences in secretion patterns, novel cardiovascular biomarkers might represent a promising diagnostic tool for HFpEF in the future. MDPI 2020-04-15 /pmc/articles/PMC7230638/ /pubmed/32326570 http://dx.doi.org/10.3390/jcm9041130 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jirak, Peter Pistulli, Rudin Lichtenauer, Michael Wernly, Bernhard Paar, Vera Motloch, Lukas J. Rezar, Richard Jung, Christian Hoppe, Uta C. Schulze, P. Christian Kretzschmar, Daniel Braun-Dullaeus, Rüdiger C. Bekfani, Tarek Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls |
title | Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls |
title_full | Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls |
title_fullStr | Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls |
title_full_unstemmed | Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls |
title_short | Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls |
title_sort | expression of the novel cardiac biomarkers sst2, gdf-15, supar, and h-fabp in hfpef patients compared to icm, dcm, and controls |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230638/ https://www.ncbi.nlm.nih.gov/pubmed/32326570 http://dx.doi.org/10.3390/jcm9041130 |
work_keys_str_mv | AT jirakpeter expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT pistullirudin expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT lichtenauermichael expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT wernlybernhard expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT paarvera expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT motlochlukasj expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT rezarrichard expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT jungchristian expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT hoppeutac expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT schulzepchristian expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT kretzschmardaniel expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT braundullaeusrudigerc expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT bekfanitarek expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols |